2016
Long-term survival in AIDS-related primary central nervous system lymphoma
Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro-Oncology 2016, 19: 99-108. PMID: 27576871, PMCID: PMC5193026, DOI: 10.1093/neuonc/now155.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyWhole brain radiotherapyPrimary central nervous system lymphomaCentral nervous system lymphomaAR-PCNSLNervous system lymphomaHD-MTXLong-term survivalMulticenter analysisSystem lymphomaAdvent of cARTLong-term disease-free survivalLonger progression-free survivalSan Francisco General HospitalHigh-dose methotrexateDisease-free survivalProgression-free survivalOptimal therapeutic approachTherapy-related factorsFirst-line interventionPost-cART eraLong-term toxicityAntiretroviral therapyBrain radiotherapyFavorable survivalPrimary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control
Nguyen D, Houillier C, Choquet S, Cassoux N, Soussain C, Le Cossec C, Legarf-Tavernier M, Costopoulos M, LeHoang P, Bodaghi B, Omuro A, Hoang-Xuan K, Touitou V. Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control. Ophthalmology 2016, 123: 2047-2050. PMID: 27137876, DOI: 10.1016/j.ophtha.2016.03.043.Peer-Reviewed Original ResearchHigh-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system
Curry RC, Faivre G, Akkari L, Joyce JA, Lin O, Rosenblum M, Diamond EL, Fisher R, Omuro A. High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system. Leukemia & Lymphoma 2016, 57: 1961-1964. PMID: 26727454, DOI: 10.3109/10428194.2015.1120867.Peer-Reviewed Original Research
2015
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial
Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio M, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy M, Hoang-Xuan K. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. The Lancet Haematology 2015, 2: e251-e259. PMID: 26688235, DOI: 10.1016/s2352-3026(15)00074-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCytarabineDacarbazineDisease-Free SurvivalFemaleHumansLymphomaMaleMethotrexateMiddle AgedProcarbazineProspective StudiesQuality of LifeTemozolomideTreatment OutcomeVincristineConceptsPrimary CNS lymphomaProgression-free survivalKarnofsky Performance Scale scoreCytarabine groupPhase 2 trialCNS lymphomaPerformance Scale scoreTemozolomide groupElderly populationScale scoreMedian progression-free survivalPhase 2 trial designCommon grade 3Methotrexate-based regimensProphylactic G-CSFMedian overall survivalStandard chemotherapy regimenPoor prognosis patientsQuality of lifeChemotherapy regimenEfficacy endpointPrimary endpointPrognosis patientsElderly patientsImmunocompetent patientsFirst-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
Kasenda B, Ferreri A, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Hoang-Xuan K, Pulczynski E, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor T, Illerhaus G, Briel M. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. Annals Of Oncology 2015, 26: 1305-1313. PMID: 25701456, PMCID: PMC4735103, DOI: 10.1093/annonc/mdv076.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreElderly PCNSL patientsFirst-line therapyHD-MTXIndividual patient dataPCNSL patientsImproved survivalEligible studiesElderly primary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphomaSystematic reviewCentral nervous system lymphomaHigh-dose methotrexatePatient dataWhole brain radiotherapyFirst-line treatmentNervous system lymphomaStrong prognostic factorElderly patientsImmunocompetent patientsProspective trialMedian ageOral chemotherapyPrognostic factorsR-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015, 125: 1403-1410. PMID: 25568347, PMCID: PMC4342354, DOI: 10.1182/blood-2014-10-604561.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsBusulfanCentral Nervous System NeoplasmsCombined Modality TherapyCyclophosphamideCytarabineFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansLymphoma, Non-HodgkinMaleMethotrexateMiddle AgedNeoplasm GradingNeoplasm StagingProcarbazinePrognosisRituximabSurvival RateThiotepaTransplantation, AutologousVincristineYoung AdultConceptsAutologous stem cell transplantProgression-free survivalHigh-dose chemotherapyPrimary central nervous system lymphomaStem cell transplantOverall survivalR-MPVHigh-dose methotrexate-based chemotherapyTwo-year progression-free survivalConsolidation high-dose chemotherapyMedian progression-free survivalCentral nervous system lymphomaMedian Karnofsky performance status 80Treatment-related deathsTwo-year OSCycles of chemotherapyMethotrexate-based chemotherapyObjective response ratePrimary end pointAcceptable toxicity profileMainstay of treatmentPhase 2 studyPrimary CNS lymphomaNervous system lymphomaBlood-brain barrier
2014
Methotrexate re-challenge for recurrent primary central nervous system lymphoma
Pentsova E, DeAngelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. Journal Of Neuro-Oncology 2014, 117: 161-165. PMID: 24481997, PMCID: PMC5256683, DOI: 10.1007/s11060-014-1370-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCentral Nervous System NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMethotrexateMiddle AgedNeoplasm Recurrence, LocalPrognosisRetreatmentRetrospective StudiesSalvage TherapyTreatment OutcomeConceptsPrimary CNS lymphomaKarnofsky performance scoreProgression-free survivalInitial diagnosisRecurrent primary central nervous system lymphomaPrimary central nervous system lymphomaMedian Karnofsky performance scoreMedian progression-free survivalCentral nervous system lymphomaObjective response rateNervous system lymphomaMedian OSCNS lymphomaFree survivalRecurrent diseaseSalvage treatmentFirst relapsePartial responsePCNSL patientsPrognostic factorsComplete responseMedian ageSystem lymphomaDisease relapseMedian time
2013
Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome
Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. Journal Of Clinical Oncology 2013, 31: 3971-3979. PMID: 24101038, PMCID: PMC5569679, DOI: 10.1200/jco.2013.50.4910.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsChemoradiotherapyCranial IrradiationCytarabineDisease-Free SurvivalFemaleHumansLymphomaMaleMethotrexateMiddle AgedProcarbazineRituximabTimeTreatment OutcomeVincristineConceptsProgression-free survivalMedian progression-free survivalMedian overall survivalPrimary CNS lymphomaOverall survivalR-MPVComplete responseCNS lymphomaMedian Karnofsky performance scoreMulticenter phase II studyLong-term disease controlEnd pointApparent diffusion coefficientExploratory end pointsKarnofsky performance scorePhase II studyPrimary end pointWhole brain radiotherapyLong-term outcomesWhite matter changesHigh response rateInduction chemotherapyStandard WBRTBrain radiotherapyII study
2012
Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center
Welch MR, Omuro A, DeAngelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro-Oncology 2012, 14: 1304-1311. PMID: 22952196, PMCID: PMC3452344, DOI: 10.1093/neuonc/nos207.Peer-Reviewed Original ResearchConceptsMemorial Sloan-Kettering Cancer CenterOlder patientsCancer CenterSurvival rateLower baseline creatinine clearanceMedian progression-free survivalTwo-year survival rateBaseline creatinine clearanceDeep brain involvementSignificant renal toxicityMedian overall survivalPrimary CNS lymphomaProgression-free survivalTertiary care centerHigh-dose MTXPredictors of survivalFifth treatment cycleOcular radiationAggressive therapyCNS lymphomaBrain involvementCreatinine clearanceMost patientsOverall survivalPCNSL patientsChemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis
Pentsova E, Rosenblum M, Holodny A, Palomba ML, Omuro A. Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis. Leukemia & Lymphoma 2012, 53: 1620-1622. PMID: 22242822, DOI: 10.3109/10428194.2012.656632.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsAutopsyBrainBrain InjuriesChlorambucilCytarabineDisease ProgressionFatal OutcomeHumansInjections, SpinalLeukemia, Lymphocytic, Chronic, B-CellMagnetic Resonance ImagingMaleMethotrexateNervous System DiseasesPositron-Emission TomographyRecurrenceWaldenstrom Macroglobulinemia
2011
Primary central nervous system lymphoma
Graber JJ, Omuro A. Primary central nervous system lymphoma. Current Opinion In Neurology 2011, 24: 633-640. PMID: 21968551, DOI: 10.1097/wco.0b013e32834cbdef.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaReduced-dose radiotherapyProgression-free survivalNervous system lymphomaNeurotoxicity ratesSystem lymphomaChemotherapy-only treatmentHigh-dose methotrexateStem cell rescueWhole brain radiotherapyHigh-dose chemotherapyPhase II studyWorse cognitive outcomesChemotherapy regimenSalvage treatmentII studyOlder patientsOverall survivalBrain damageChemotherapyRadiotherapyAdditional neurotoxicityRoutine practiceNeuropsychological evaluationCognitive functions in primary CNS lymphoma after single or combined modality regimens
Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, Thaler HT. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-Oncology 2011, 14: 101-108. PMID: 22013168, PMCID: PMC3245999, DOI: 10.1093/neuonc/nor186.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyPrimary CNS lymphomaQuality of lifeHD-MTXWhite matter diseaseModality regimenCNS lymphomaHigh-dose methotrexate-based chemotherapyCognitive impairmentExtensive white matter diseaseMethotrexate-based chemotherapySubset of patientsBaseline neuropsychological evaluationBrain radiotherapyDisease remissionModality regimensMost cognitive domainsStandard treatmentTreatment completionCognitive dysfunctionSufficient severityPatientsNeuropsychological evaluationCognitive functionSubstantial riskProphylactic intrathecal chemotherapy in primary CNS lymphoma
Sierra del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A, Kaloshi G, Elhallani S, Omuro A, Choquet S, Soussain C, Hoang-Xuan K. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. Journal Of Neuro-Oncology 2011, 106: 143-146. PMID: 21739169, DOI: 10.1007/s11060-011-0649-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansInjections, SpinalKarnofsky Performance StatusLomustineLymphomaMaleMethotrexateMethylprednisoloneMiddle AgedNeoplasm Recurrence, LocalNeuroprotective AgentsProcarbazineRetrospective StudiesYoung AdultConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaNervous system lymphomaProphylactic intrathecal chemotherapyIntrathecal chemotherapySystem lymphomaIntrathecal prophylaxisHigh-dose intravenous methotrexateRetrospective single-center studyObjective response ratePatterns of relapsePrimary CNS lymphomaProgression-free survivalSingle-center studyHigh intravenous dosesIntrathecal chemoprophylaxisIntravenous methotrexateProphylaxis withdrawalChemotherapy regimenCNS lymphomaSystemic chemotherapyKarnofsky indexOverall survivalIntravenous dosesMedian ageMethotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy
Morris PG, Abrey LE, Reiner AS, Wu N, Panageas KS, Seko BS, Deangelis LM, Omuro A. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leukemia & Lymphoma 2011, 52: 1891-1897. PMID: 21699456, DOI: 10.3109/10428194.2011.585527.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCentral Nervous System NeoplasmsCombined Modality TherapyCytarabineFemaleHumansKarnofsky Performance StatusMaleMethotrexateMiddle AgedProcarbazinePrognosisRituximabSurvival AnalysisVincristineConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaProgression-free survivalNervous system lymphomaMTX AUCMethotrexate areaSystem lymphomaMedian Karnofsky performance status (KPS) scoreIntra-patient dose escalationProspective phase II trialKarnofsky performance status scoreLow-dose radiotherapyFirst chemotherapy cyclePerformance status scorePhase II trialImproved tumor controlSubstantial inter-individual variabilityChemotherapy cyclesII trialMTX exposureOverall survivalDose escalationMedian agePrognostic factorsInter-individual variabilityPharmacotherapy for Primary CNS Lymphoma
Graber JJ, Omuro A. Pharmacotherapy for Primary CNS Lymphoma. CNS Drugs 2011, 25: 447-457. PMID: 21649446, DOI: 10.2165/11589030-000000000-00000.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaCNS lymphomaHigh-dose methotrexate-based chemotherapyMore effective chemotherapy regimensRefractory primary CNS lymphomaEffective chemotherapy regimensOptimal chemotherapy combinationReduced-dose radiotherapySingle-agent methotrexateMethotrexate-based chemotherapyStem cell rescueWhole brain radiotherapyHigh-dose chemotherapyLong-term remissionProgression-free survivalOngoing clinical trialsCombination of drugsChemotherapy regimensChemotherapy combinationsChemotherapy optionsRadiotherapy resultsSerious complicationsClinical trialsCell rescueConsolidation treatment
2007
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly
Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. Journal Of Neuro-Oncology 2007, 85: 207-211. PMID: 17896079, DOI: 10.1007/s11060-007-9397-0.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaIntra-thecal chemotherapyFavorable toxicity profileComplete responseToxicity profilePrimary central nervous system lymphomaMedian event-free survivalCentral nervous system lymphomaMedian overall survivalEvent-free survivalNervous system lymphomaNew alternative treatmentLow response rateInduction chemotherapyInnovative regimenCNS lymphomaElderly patientsIntestinal obstructionOverall survivalPCNSL patientsYounger patientsSystem lymphomaConsecutive seriesEfficacy resultsGrade 3
2005
Chemoradiotherapy for primary CNS lymphoma
Omuro AM, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma. Neurology 2005, 64: 69-74. PMID: 15642906, DOI: 10.1212/01.wnl.0000148641.98241.5e.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaLong-term outcomesComplete responsePartial responseCNS lymphomaMedian Karnofsky Performance Scale scoreMedian disease-free survivalProspective phase II trialKarnofsky Performance Scale scoreIncidence of neurotoxicityWhole brain radiotherapyMedian overall survivalDisease-free survivalPhase II trialYear of diagnosisPerformance Scale scoreChemotherapy regimenChemotherapy regimensFifteen patientsFirst relapseII trialMinor complicationsOverall survivalModality treatmentDisease progression